Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with A

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
40 Q3 2021 ACACIA ORAL POWDER 1231.00 mg Correction
40 Q4 2021 ACACIA ORAL POWDER 800.00 mg Correction
137 Q4 2021 ACRYLATES COPOLYMER TOPICAL SOLUTION 5.40 %w/w Correction
331 Q4 2021 ANHYDROUS CITRIC ACID BUCCAL FILM, SOLUBLE 3 mg Correction
42 Q3 2021 ACACIA ORAL POWDER, FOR SUSPENSION 648.00 mg MDE Replacement
42 Q4 2021 ACACIA ORAL POWDER, FOR SUSPENSION 7386 mg MDE Replacement
57 Q3 2021 ACESULFAME ORAL SOLUTION 4.00 mg/ 1.00 ml MDE Replacement
57 Q4 2021 ACESULFAME ORAL SOLUTION 120 mg MDE Replacement
64 Q3 2021 ACESULFAME POTASSIUM ORAL SOLUTION 200.00 mg MDE Replacement
64 Q4 2021 ACESULFAME POTASSIUM ORAL SOLUTION 288 mg MDE Replacement
66 Q3 2021 ACESULFAME POTASSIUM ORAL TABLET 27.80 mg MDE Replacement
66 Q4 2021 ACESULFAME POTASSIUM ORAL TABLET 111.2 mg MDE Replacement
70 Q3 2021 ACESULFAME POTASSIUM ORAL TABLET, FOR SUSPENSION 1.80 mg MDE Replacement
70 Q4 2021 ACESULFAME POTASSIUM ORAL TABLET, FOR SUSPENSION 7.2 mg MDE Replacement
128 Q3 2021 ACRYL-EZE 93018509 WHITE ORAL TABLET 76.68 mg MDE Replacement
128 Q4 2021 ACRYL-EZE 93018509 WHITE ORAL TABLET 153.36 mg MDE Replacement
159 Q3 2021 ALCOHOL INTRAMUSCULAR INJECTION 20.00 %w/v MDE Replacement
159 Q4 2021 ALCOHOL INTRAMUSCULAR INJECTION 1000 mg MDE Replacement
164 Q3 2021 ALCOHOL INTRAVENOUS INJECTION, EMULSION 2.85 %w/v MDE Replacement
164 Q4 2021 ALCOHOL INTRAVENOUS INJECTION, EMULSION 520 mg MDE Replacement
183 Q3 2021 ALCOHOL ORAL SUSPENSION 72.50 mg MDE Replacement
183 Q4 2021 ALCOHOL ORAL SUSPENSION 520 mg MDE Replacement
185 Q3 2021 ALCOHOL ORAL SYRUP 81.30 mg/ 1.00 ml MDE Replacement
185 Q4 2021 ALCOHOL ORAL SYRUP 21000 mg MDE Replacement
193 Q3 2021 ALCOHOL SUBLINGUAL SPRAY 49.60 mg/ 1.00 ml MDE Replacement
193 Q4 2021 ALCOHOL SUBLINGUAL SPRAY 396.8 mg MDE Replacement
198 Q3 2021 ALCOHOL TOPICAL GEL, METERED 72.60 %w/w MDE Replacement
198 Q4 2021 ALCOHOL TOPICAL GEL, METERED 525 mg MDE Replacement
237 Q3 2021 ALUMINUM POLYESTER TRANSDERMAL FILM, EXTENDED RELEASE 81.00 mg MDE Replacement
237 Q4 2021 ALUMINUM POLYESTER TRANSDERMAL FILM, EXTENDED RELEASE 81 mg MDE Replacement
240 Q3 2021 ALUMINUM SILICATE ORAL TABLET, EXTENDED RELEASE 94.00 mg MDE Replacement
240 Q4 2021 ALUMINUM SILICATE ORAL TABLET, EXTENDED RELEASE 94 mg MDE Replacement
242 Q3 2021 ALUMINUM SILICATE TOPICAL SYSTEM 18.90 mg MDE Replacement
242 Q4 2021 ALUMINUM SILICATE TOPICAL SYSTEM 18.9 mg MDE Replacement
245 Q3 2021 ALUMINUM STEARATE ORAL CAPSULE, EXTENDED RELEASE 0.40 mg MDE Replacement
245 Q4 2021 ALUMINUM STEARATE ORAL CAPSULE, EXTENDED RELEASE 0.8 mg MDE Replacement
246 Q3 2021 ALUMINUM STEARATE ORAL TABLET 2.80 mg MDE Replacement
246 Q4 2021 ALUMINUM STEARATE ORAL TABLET 5.6 mg MDE Replacement
287 Q3 2021 AMMONIA SOLUTION ORAL TABLET, EXTENDED RELEASE NA MDE Replacement
287 Q4 2021 AMMONIA SOLUTION ORAL TABLET, EXTENDED RELEASE 5.9 mg MDE Replacement
296 Q3 2021 AMMONIO METHACRYLATE COPOLYMER TYPE A ORAL CAPSULE, EXTENDED RELEASE 42.40 mg MDE Replacement
296 Q4 2021 AMMONIO METHACRYLATE COPOLYMER TYPE A ORAL CAPSULE, EXTENDED RELEASE 63.6 mg MDE Replacement
300 Q3 2021 AMMONIO METHACRYLATE COPOLYMER TYPE B ORAL CAPSULE 109.56 mg MDE Replacement
300 Q4 2021 AMMONIO METHACRYLATE COPOLYMER TYPE B ORAL CAPSULE 219.12 mg MDE Replacement
301 Q3 2021 AMMONIO METHACRYLATE COPOLYMER TYPE B ORAL CAPSULE, EXTENDED RELEASE 91.88 mg MDE Replacement
301 Q4 2021 AMMONIO METHACRYLATE COPOLYMER TYPE B ORAL CAPSULE, EXTENDED RELEASE 178.34 mg MDE Replacement
305 Q3 2021 AMMONIO METHACRYLATE COPOLYMER TYPE B ORAL TABLET, FILM COATED 8.00 mg MDE Replacement
305 Q4 2021 AMMONIO METHACRYLATE COPOLYMER TYPE B ORAL TABLET, FILM COATED 32 mg MDE Replacement
311 Q3 2021 AMMONIUM CHLORIDE ORAL TABLET 4.20 mg MDE Replacement
311 Q4 2021 AMMONIUM CHLORIDE ORAL TABLET 8.4 mg MDE Replacement
328 Q3 2021 ANHYDROUS CITRIC ACID INTRACARDIAC INJECTION 0.25 %w/v MDE Replacement
328 Q4 2021 ANHYDROUS CITRIC ACID INTRACARDIAC INJECTION 22.5 mg MDE Replacement
329 Q3 2021 ANHYDROUS CITRIC ACID INTRAMUSCULAR INJECTION 0.33 %w/v MDE Replacement
329 Q4 2021 ANHYDROUS CITRIC ACID INTRAMUSCULAR INJECTION 22.5 mg MDE Replacement
332 Q3 2021 ANHYDROUS CITRIC ACID INTRAVENOUS INJECTION 166.00 mg MDE Replacement
332 Q4 2021 ANHYDROUS CITRIC ACID INTRAVENOUS INJECTION 510 mg MDE Replacement
346 Q3 2021 ANHYDROUS CITRIC ACID ORAL GRANULE, FOR SUSPENSION 4.90 mg MDE Replacement
346 Q4 2021 ANHYDROUS CITRIC ACID ORAL GRANULE, FOR SUSPENSION 29.4 mg MDE Replacement
359 Q3 2021 ANHYDROUS CITRIC ACID ORAL TABLET, CHEWABLE, EXTENDED RELEASE 8.00 mg MDE Replacement
359 Q4 2021 ANHYDROUS CITRIC ACID ORAL TABLET, CHEWABLE, EXTENDED RELEASE 12 mg MDE Replacement
366 Q3 2021 ANHYDROUS CITRIC ACID SUBCUTANEOUS INJECTION 0.25 %w/v MDE Replacement
366 Q4 2021 ANHYDROUS CITRIC ACID SUBCUTANEOUS INJECTION 22.5 mg MDE Replacement
385 Q3 2021 ANHYDROUS DEXTROSE INTRAVENOUS INJECTION 2000.00 mg MDE Replacement
385 Q4 2021 ANHYDROUS DEXTROSE INTRAVENOUS INJECTION 2700 mg MDE Replacement
388 Q3 2021 ANHYDROUS DEXTROSE NASAL SPRAY, METERED 50.00 mg MDE Replacement
388 Q4 2021 ANHYDROUS DEXTROSE NASAL SPRAY, METERED 200 mg MDE Replacement
389 Q3 2021 ANHYDROUS DEXTROSE ORAL GRANULE, FOR SUSPENSION 2813.00 mg MDE Replacement
389 Q4 2021 ANHYDROUS DEXTROSE ORAL GRANULE, FOR SUSPENSION 16878 mg MDE Replacement
391 Q3 2021 ANHYDROUS DEXTROSE ORAL TABLET, EXTENDED RELEASE 15.00 mg MDE Replacement
391 Q4 2021 ANHYDROUS DEXTROSE ORAL TABLET, EXTENDED RELEASE 30 mg MDE Replacement
396 Q3 2021 ANHYDROUS DIBASIC CALCIUM PHOSPHATE ORAL CAPSULE, DELAYED RELEASE 381.00 mg MDE Replacement
396 Q4 2021 ANHYDROUS DIBASIC CALCIUM PHOSPHATE ORAL CAPSULE, DELAYED RELEASE 381 mg MDE Replacement
406 Q3 2021 ANHYDROUS DIBASIC CALCIUM PHOSPHATE ORAL TABLET, FOR SUSPENSION 101.50 mg MDE Replacement
406 Q4 2021 ANHYDROUS DIBASIC CALCIUM PHOSPHATE ORAL TABLET, FOR SUSPENSION 406 mg MDE Replacement
407 Q3 2021 ANHYDROUS DIBASIC CALCIUM PHOSPHATE SUBLINGUAL POWDER 10.00 mg MDE Replacement
407 Q4 2021 ANHYDROUS DIBASIC CALCIUM PHOSPHATE SUBLINGUAL POWDER 30 mg MDE Replacement
427 Q3 2021 ANHYDROUS LACTOSE ORAL TABLET, FILM COATED 622.21 mg MDE Replacement
427 Q4 2021 ANHYDROUS LACTOSE ORAL TABLET, FILM COATED 622.21 mg MDE Replacement
504 Q3 2021 ASCORBIC ACID ORAL CAPSULE, EXTENDED RELEASE 0.40 mg MDE Replacement
504 Q4 2021 ASCORBIC ACID ORAL CAPSULE, EXTENDED RELEASE 0.8 mg MDE Replacement
506 Q3 2021 ASCORBIC ACID ORAL POWDER, FOR SOLUTION 200.00 mg MDE Replacement
506 Q4 2021 ASCORBIC ACID ORAL POWDER, FOR SOLUTION 560 mg MDE Replacement
540 Q3 2021 ASPARTAME ORAL TABLET, CHEWABLE, EXTENDED RELEASE 12.00 mg MDE Replacement
540 Q4 2021 ASPARTAME ORAL TABLET, CHEWABLE, EXTENDED RELEASE 18 mg MDE Replacement
542 Q3 2021 ASPARTAME ORAL TABLET, FOR SUSPENSION 3.70 mg MDE Replacement
542 Q4 2021 ASPARTAME ORAL TABLET, FOR SUSPENSION 14.8 mg MDE Replacement
127 Q4 2021 ACETYLTRIBUTYL CITRATE TOPICAL SPONGE 5.40 %w/w Deletion
448 Q4 2021 ANHYDROUS TRISODIUM CITRATE ORAL SYRUP 7.95 mg/ 5.00 ml Deletion

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: September 30, 2021
Database Last Updated: October 21, 2021

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English